Clinical Obesity and All-Cause and Cause-Specific Mortality in UK Biobank  JAMA Intern Med. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41143828

Combining Medications With Bariatric Surgery to Treat Obesity  JAMA. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41182882

Current and Future Medications for Obesity Treatment  JAMA. 2025;334(17):1551–1552
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40932726

The Forcing Factors of Physical Inactivity and Obesity in the United States - An Artificial Intelligence Analysis of an Ecological Framework  American Journal of Medicine. 2025;138(11):1550–1556
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40393611

Grip Strength Linked to Lower Risk of Obesity-Related Disease and Death  JAMA. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41134568

In adults with obesity but without type 2 diabetes, tirzepatide increased weight loss at 72 wk compared with semaglutide Annals of Internal Medicine. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41183340

In adults with overweight or obesity and ≥5% weight loss, a patient-delivered intervention reduced weight regain at 18 mo  Annals of Internal Medicine. 2025;178(10):Jc111
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41052441

In patients with AF and obesity, catheter ablation vs. lifestyle modification plus antiarrhythmic drugs improved AF freedom at 1 y  Annals of Internal Medicine. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41183348

Low dose oral semaglutide for obesity . . . and other research  BMJ. 2025;391:r2050
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41067754

McGee’s Evidence-Based Physical Diagnosis. Elsevier; 2026 
Available from: https://catalogue.health.wa.gov.au/record=b3414867~S10

Moving Beyond BMI to Define Obesity  JAMA Intern Med. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41143790

Normal BMI With Abdominal Obesity Associated With Cardiometabolic Risks  JAMA. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41171291

The role of GLP-1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system  Medical Journal of Australia. 2025;223(7):380
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40879113

The role of GLP-1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system  Medical Journal of Australia. 2025;223(7):379
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=40879111

Tirzepatide vs. Semaglutide for Obesity Treatment  New England Journal of Medicine. 2025;393(16):1654–1655
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41124642

Tirzepatide vs. Semaglutide for Obesity Treatment  New England Journal of Medicine. 2025;393(16):1655
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41124643

Tirzepatide vs. Semaglutide for Obesity Treatment. Reply  New England Journal of Medicine. 2025;393(16):1655–1656
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=41124644